IRIS
PINATO, David James
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.333
NA - Nord America 1.519
AS - Asia 655
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 1
Totale 4.511
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.509
IE - Irlanda 1.234
SE - Svezia 332
SG - Singapore 300
IT - Italia 258
HK - Hong Kong 215
UA - Ucraina 169
DE - Germania 131
FR - Francia 89
CN - Cina 63
FI - Finlandia 57
IN - India 29
IR - Iran 28
NL - Olanda 16
CZ - Repubblica Ceca 12
CA - Canada 10
GB - Regno Unito 9
JP - Giappone 8
VN - Vietnam 8
BE - Belgio 7
CH - Svizzera 5
RU - Federazione Russa 5
PL - Polonia 4
AT - Austria 3
EU - Europa 3
LI - Liechtenstein 2
PK - Pakistan 2
CO - Colombia 1
KR - Corea 1
TR - Turchia 1
Totale 4.511
Salva come PNG Salva come JPEG
Città #
Dublin 1.231
Hong Kong 215
Singapore 200
Lawrence 149
Princeton 149
Jacksonville 139
Wilmington 138
San Mateo 125
Chandler 113
Dearborn 55
Piemonte 46
Ann Arbor 38
Ashburn 35
Helsinki 31
Boardman 27
Novara 26
Andover 23
Strasbourg 22
Vercelli 21
Beijing 20
Bremen 18
Santa Clara 18
Turin 17
Zanjan 16
Norwalk 14
Milan 13
Amsterdam 12
Pleasantville 12
Woodbridge 11
Houston 10
West Jordan 10
Dong Ket 8
Brno 7
Brussels 7
Los Angeles 7
Munich 7
Nanjing 7
Mezzomerico 6
Hangzhou 5
Hefei 5
Kunming 5
Toronto 5
Zurich 5
Cassano Magnago 4
Kitakyushu 4
New York 4
Düsseldorf 3
Fairfield 3
Frankfurt am Main 3
Kraków 3
Leipzig 3
Minamiyukigaya 3
Pardubice 3
Sacramento 3
Schwabmünchen 3
Augusta 2
Bologna 2
Borgomanero 2
Cambridge 2
Chicago 2
Deiva Marina 2
Delhi 2
Des Moines 2
Dreieich 2
Fort Worth 2
Genoa 2
Grafing 2
Jinan 2
Leawood 2
Legnano 2
Magnago 2
Meppel 2
Moncalieri 2
Monmouth Junction 2
Mumbai 2
Nanchang 2
New Delhi 2
Odalengo Grande 2
Ottawa 2
Philadelphia 2
Prague 2
Redwood City 2
Rome 2
Ryazan 2
Seattle 2
Verona 2
Vienna 2
Villasanta 2
Ardabil 1
Asahikawa 1
Baotou 1
Berlin 1
Biella 1
Brixton 1
Changchun 1
Duncan 1
Forno Canavese 1
Fuzhou 1
Garden City 1
Gatchina 1
Totale 3.145
Salva come PNG Salva come JPEG
Nome #
Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. 93
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 66
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 66
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 66
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: A multi-center comparative study 66
Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19 63
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 61
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 61
Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe 56
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study 55
The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development 54
HBV AND LYMPHOMAGENESIS: NOVEL INSIGHTS INTO AN OCCULT RELATIONSHIP 51
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study 50
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 50
Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. 48
Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of patients with cancer who recovered from SARS-Cov-2 infection: results from the OnCovid registry. 47
Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis 46
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: The OnCovid Inflammatory Score 46
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship 45
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study 45
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 45
L’impatto del Long COVID è stato minore nella terza ondata della pandemia rispetto alla prima ondata in una popolazione italiana di 324 pazienti. 44
GENDER-RELATED DISTRIBUTION OF THE INTERLEUKIN-1BETA AND INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISMS IN PATIENTS WITH END-STAGE LIVER DISEASE 44
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 43
The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma 42
INTERLEUKIN-6 POLYMORPHISMS AND GENDER: RELATIONSHIP WITH THE OCCURRENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH END-STAGE LIVER DISEASE 41
The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application 41
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 40
Reliability and reproducibility of the edmondson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens 39
Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma 39
Tissue biomarkers of prognostic significance in hepatocellular carcinoma. 38
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 37
Advanced age influences the dynamic changes in circulating C-reactive protein following injury 36
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 36
Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study 35
Back from the brink: EGFR inhibition in gastroesophageal cancer 35
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach 35
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 35
Artemisia: A divine dart against cancer? 34
Antibiotic therapy and outcome from immune-checkpoint inhibitors 34
The systemic pro-inflammatory response: targeting the dangerous liaisonbetween COVID-19 and cancer 34
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 33
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 31
Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer 31
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis 31
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma 31
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 30
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma 29
Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients with Cancer - Reply 29
Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway 28
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 28
Antibiotic-induced Dysbiosis as a Putative Actionable Driver of Cancer Immunity in Renal Cell Carcinoma 28
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 28
An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma 27
A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI) 27
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma 27
Biliary tract cancers: Molecular heterogeneity and new treatment options 27
Acceleration of interstitial lung disease induced by raltitrexed 27
Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated with Immune Checkpoint Inhibitor Therapy 27
Isogeneic comparison of primary and metastatic lung cancer identifies CX3CR1 as a molecular determinant of site-specific metastatic diffusion 26
Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy 26
The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma 26
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 26
Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: A network meta-analysis 26
Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer 26
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers 25
Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer 25
COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response 25
T-cell mediated responses against alpha-foetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patients’ survival 25
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy 25
A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: The prognostic nutritional index (PNI) 24
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 24
Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association? 23
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors 23
Evaluating the impact of COVID-19 on supportive care needs, psychological distress and quality of life in UK cancer survivors and their support network 23
Blood Epstein–Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma 23
Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients 22
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective 21
An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: Correlation with tumour phenotype and survival outcomes 21
An unexpected cause of pulmonary cannonball lesion 21
Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study 21
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study 21
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 21
PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects 21
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 20
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 20
CD24: A potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma 20
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials 20
Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials 20
Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance 20
Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: Adjunctive role of the albi grade 20
Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinoma 20
Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma 20
The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer 20
Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression 19
Cancer-related inflammation: An emerging prognostic domain in metastatic castration-resistant prostate carcinoma 19
Inflammation as a validated prognostic determinant in carcinoma of unknown primary site 19
Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations 19
Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior 19
TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition 19
Totale 3.365
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.827
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.827
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020241 0 0 0 2 39 35 56 21 32 29 26 1
2020/2021400 29 0 24 1 28 5 28 5 26 113 128 13
2021/2022799 27 2 174 71 46 6 24 21 68 63 126 171
2022/20231.810 217 43 77 6 51 106 43 79 1.132 5 27 24
2023/20241.084 136 46 82 33 209 14 222 15 4 39 56 228
2024/2025281 45 26 204 6 0 0 0 0 0 0 0 0
Totale 4.804